Korea's regulator approved Hanmi Pharmaceutical's efpeglenatide, the first homegrown GLP-1 obesity drug, after patients lost 9.02% of body weight in 40 weeks. That is less than Wegovy and Mounjaro showed in longer trials, so Hanmi's case rests on milder side effects and a price for long-term patients that it has not yet set.
Reality
- Evidence60
- Adoption
- Insufficient
- Hype gap+20
- Incentives55
- Confidence58
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+20
- Incentives70
- Confidence45
UKHSA has 259 confirmed cases, one death, an investigation running since May, and implicated venues that were buying eggs from several suppliers at once, which is the combination that makes a targeted withdrawal impossible.
Reality
- Evidence44
- Adoption
- Insufficient
- Hype gap−14
- Incentives38
- Confidence46
One death and 487 severe cases out of 522,000 reported infections put the exposure in Korea's fixed 4.84 million doses and a two-week rollout window, not in supply chains.
Reality
- Evidence58
- Adoption62
- Hype gap+27
- Incentives66
- Confidence52
The ring-shaped blood pressure monitor is already in 38 of Korea's 47 tertiary hospitals. The KOSDAQ listing asks investors to fund two more loss-making years before the thesis pays.
Reality
- Evidence33
- Adoption54
- Hype gap+34
- Incentives86
- Confidence44